The Potential of Bacteriophage Therapy as an Alternative Treatment Approach for Antibiotic-Resistant Infections

被引:8
作者
Walter, Nike [1 ,2 ]
Mirzaei, Mohammadali [3 ,4 ]
Deng, Li [4 ,5 ]
Willy, Christian [5 ]
Alt, Volker [1 ]
Rupp, Markus [1 ]
机构
[1] Univ Hosp Regensburg, Dept Trauma Surg, Regensburg, Germany
[2] Univ Hosp Regensburg, Dept Psychosomat Med, Regensburg, Germany
[3] Helmholtz Ctr Munich, Inst Virol, German Res Ctr Environm Hlth, Munich, Germany
[4] Tech Univ Munich, Inst Virol, Munich, Germany
[5] Mil Acad Hosp Berlin, Res & Treatment Ctr Sept Defect Wounds, Dept Trauma & Orthoped Surg, Sept & Reconstruct Surg,Fed Armed Forces Germany, Berlin, Germany
关键词
Bacteriophages; Phage therapy; Randomized-controlled trials; PHAGE THERAPY; TRIAL;
D O I
10.1159/000534717
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This study aimed to provide a comprehensive overview of the current state of the literature on the therapeutical application of bacteriophages. Methods: First, a bibliometric analysis was performed using the database Web of Science to determine annual number of publications and citations. Second, a systematic literature review was conducted on randomized-controlled trials (RCTs) of phage therapy in PubMed. Results: Over the past decade, the number of publications on bacteriophage therapy increased more than fourfold with 212 articles in 2011 and 739 in 2022. The systematic search in PubMed yielded 7 RCTs eligible for inclusion, reporting on a total of 418 participants. Identified indications in this study included bacterial diarrhea, urinary tract infections, infected burn wounds, chronic otitis, chronic venous leg ulcers, and chronic rhinosinusitis. In three studies, mild to moderate adverse events were reported in 10/195 participants (5.1%). Three of the studies reported a statistically significant difference in outcomes comparing phage therapy with standard of care or placebo. Conclusion: Phage therapy has gained increasing interest over the years. RCTs on different indications suggest the safety of phage therapy; however, reasons why phage therapy is not yet well accepted are limitations in the study designs. For a successful translation into clinical practice researchers and clinicians should learn from the earlier experiences and consider issues such as the quality of phage preparation, sensitivity testing, titer and dosages, as well as access to the infection site and stability for standardized protocols and future trials.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 50 条
[41]   A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens [J].
Wittebole, Xavier ;
De Roock, Sophie ;
Opal, Steven M. .
VIRULENCE, 2014, 5 (01) :226-235
[42]   Successful Treatment of Antibiotic-resistant, Poly-microbial Bone Infection With Bacteriophages and Antibiotics Combination [J].
Nir-Paz, Ran ;
Gelman, Daniel ;
Khouri, Ayman ;
Sisson, Brittany M. ;
Fackler, Joseph ;
Alkalay-Oren, Sivan ;
Khalifa, Leron ;
Rimon, Amit ;
Yerushalmy, Ortal ;
Bader, Reem ;
Amit, Sharon ;
Coppenhagen-Glazer, Shunit ;
Henry, Matthew ;
Quinones, Javier ;
Malagon, Francisco ;
Biswas, Biswajit ;
Moses, Allon E. ;
Merril, Greg ;
Schooley, Robert T. ;
Brownstein, Michael J. ;
Weil, Yoram A. ;
Hazan, Ronen .
CLINICAL INFECTIOUS DISEASES, 2019, 69 (11) :2015-2018
[43]   Phage formulations and delivery strategies: Unleashing the potential against antibiotic-resistant bacteria [J].
Bolsan, Alice Chiapetti ;
Sampaio, Gabrielli Vaz ;
Rodrigues, Heloisa Campeao ;
De Souza, Samara Silva ;
Edwiges, Thiago ;
De Pra, Marina Celant ;
Gabiatti, Naiana Cristine .
MICROBIOLOGICAL RESEARCH, 2024, 282
[44]   Bacteriophage EPP-1, a potential antibiotic alternative for controlling edwardsiellosis caused by Edwardsiella piscicida while mitigating drug-resistant gene dissemination [J].
Han, Ganghua ;
Huang, Ting ;
Liu, Xinchun ;
Liu, Ruyin .
SCIENTIFIC REPORTS, 2024, 14 (01)
[45]   Biological and molecular characterization of fEg-Eco19, a lytic bacteriophage active against an antibiotic-resistant clinical Escherichia coli isolate [J].
Badawy, Shimaa ;
Baka, Zakaria A. M. ;
Abou-Dobara, Mohamed, I ;
El-Sayed, Ahmed K. A. ;
Skurnik, Mikael .
ARCHIVES OF VIROLOGY, 2022, 167 (05) :1333-1341
[46]   Potential of Bacteriophage Therapy: A Double Edge Sword to Combat COVID-19 and Associated Pulmonary Bacterial Infections [J].
Bhargava, Kanika ;
Nath, G. ;
Aseri, G. K. ;
Jain, Neelam .
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 83 (06) :1081-1093
[47]   Bacteriophage therapy as an alternative biocontrol against emerging multidrug resistant E. coli in broilers [J].
Eid, Samah ;
Tolba, Hala M. N. ;
Hamed, Rehab, I ;
Al-Atfeehy, Nayera M. .
SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2022, 29 (05) :3380-3389
[48]   Phage therapy: an alternative treatment modality for MDR bacterial infections [J].
Pal, Namrata ;
Sharma, Poonam ;
Kumawat, Manoj ;
Singh, Samradhi ;
Verma, Vinod ;
Tiwari, Rajnarayan R. ;
Sarma, Devojit Kumar ;
Nagpal, Ravinder ;
Kumar, Manoj .
INFECTIOUS DISEASES, 2024, 56 (10) :785-817
[49]   Phage vB_Ec_ZCEC14 to treat antibiotic-resistant Escherichia coli isolated from urinary tract infections [J].
Ismael, Nedaa M. ;
Azzam, Mohamed ;
Abdelmoteleb, Mohamed ;
El-Shibiny, Ayman .
VIROLOGY JOURNAL, 2024, 21 (01)
[50]   Phage vB_Ec_ZCEC14 to treat antibiotic-resistant Escherichia coli isolated from urinary tract infections [J].
Nedaa M. Ismael ;
Mohamed Azzam ;
Mohamed Abdelmoteleb ;
Ayman El-Shibiny .
Virology Journal, 21